Skip to main content
. Author manuscript; available in PMC: 2014 Jun 15.
Published in final edited form as: Clin Cancer Res. 2013 May 2;19(12):3121–3129. doi: 10.1158/1078-0432.CCR-12-3077

Figure 2.

Figure 2

Overall survival of the initial series of 30 leukemic MCL patients according to miR-34a expression level categorized with Maxstat software. Patients with low levels of miR-34a showed worse prognosis (median OS: 15 months) compared to patients with higher miR-34a levels (median OS: 149.3 months) (P = 0.008).